Posted by Michael Wonder on 01 Apr 2019
Ziopharm Oncology announces FDA fast track designation for Ad-RTS-hIL-12 plus veledimex for the treatment of recurrent glioblastoma
1 April 2019 - Ziopharm Oncology today announced that the U.S. FDA has granted fast track designation for its Controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex, for the treatment of recurrent or progressive glioblastoma multiforme in adults.
Data previously presented suggest that Ad-RTS-hIL-12 with 20mg veledimex improves the median overall survival (mOS) from 6 to 9 months seen with available therapies to 12.7 months, with further improvement in mOS to 17.8 months in a subset of subjects with reduced cumulative steroid exposure during the active dosing period of veledimex.
